NantOmics
NantOmics provides molecular profiling for cancer patients. Its services, including GPS Cancer, use integrated DNA, RNA, and proteomic analysis.
Secondary Market Price
How NantOmics Measures Up
To help you manage your NantOmics equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series A
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of NantOmics's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future NantOmics Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for NantOmics's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
NantOmics is a molecular diagnostics company that provides testing to inform personalized cancer treatment. The company utilizes an integrated panomic approach that combines whole genome sequencing of tumor and normal samples, RNA sequencing, and quantitative proteomics. This process generates a comprehensive molecular profile of a patient's cancer. Using a proprietary analytical platform and knowledge database, NantOmics identifies disrupted biological pathways and matches genomic and proteomic alterations to potential targeted therapies, providing decision support for healthcare providers. Founded by Dr. Patrick Soon-Shiong, NantOmics is part of the NantWorks ecosystem of companies, which was established in 2011. The company is noted as the first to employ this type of integrated panomic analysis for cancer care.
The company has not publicly disclosed specific future plans or recent announcements.
- Allscripts
- BlackBerry
- Celgene
- Kuwait Investment Authority
- Patrick Soon-Shiong
- Verizon Ventures
- Co-Founder, Patrick Soon-Shiong
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is NantOmics worth joining?
Deciding to join a private company like NantOmics requires evaluating its growth potential and your personal compensation package. Platforms like Prospect can help you understand the potential value of a startup's equity to make a more informed career decision.
What should I do with my NantOmics stock?
Managing private company stock involves complex decisions around exercising options, selling shares, and planning for taxes. Using a service like Prospect can provide you with customized strategies to help optimize your equity and maximize its post-tax value.
Can you sell NantOmics stock?
As a private company, selling NantOmics stock is typically only possible during specific liquidity events, such as a tender offer or secondary sale. When these opportunities arise, tools from Prospect can help you decide if and how much to sell for optimal tax efficiency.
How can I find the value of my NantOmics stock?
The official value of private stock is determined by a 409A valuation, but forecasting its future potential is more complex. Prospect uses machine learning models and investor-grade data to project a likely range of outcomes for your startup equity.
What is NantOmics's equity worth?
The true worth of private equity is uncertain until a liquidity event like an IPO or acquisition occurs. You can use Prospect's predictive models to get a data-driven forecast of your equity's potential future value.
What is NantOmics's stock ticker symbol?
Because it is a private company, NantOmics is not traded on a public stock exchange and therefore does not have a stock ticker symbol. Ticker symbols are only assigned to companies after they complete an Initial Public Offering (IPO).
Can I buy or sell NantOmics stock?
Buying stock in a private company is typically restricted to employees exercising options or accredited investors, while selling is limited to company-approved liquidity events. When an opportunity to sell arises, Prospect can help you create a tax-optimized strategy for your shares.
What is the criteria to buy or invest in NantOmics stock?
Investing in a private company like NantOmics is generally limited to employees receiving equity compensation or accredited investors who meet specific financial criteria defined by regulators. These rules exist due to the high-risk and illiquid nature of private market investments.
